Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 340 results for eq-5d

  1. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

    Technology appraisal guidance
    Last updated
    21 April 2021
    View recommendations

    Sections for TA517

  2. Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

    Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Last updated
    3 July 2024
    View recommendations

    Sections for TA688

  3. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)

    Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.

    Technology appraisal guidance
    Published
    12 February 2025
    View recommendations

    Sections for TA1033

  4. Sarilumab for moderate to severe rheumatoid arthritis (TA485)

    Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    1 November 2017
    View recommendations

    Sections for TA485

  5. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA764

  6. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.

    Technology appraisal guidance
    Published
    31 July 2019
    View recommendations

    Sections for TA591

  7. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    22 November 2017
    View recommendations

    Sections for TA489

  8. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747

  9. Cost effectiveness of daycare units for treating patients with an acute painful sickle cell episode:- Are daycare units cost effective compared with emergency settings for treating patients with an acute painful sickle cell episode?

    Data should be collected using validated measure(s) of HRQoL, including EQ-5D Source guidance details Comes from guidance Sickle cell

    Research recommendation
    Published
    9 June 2015

  10. For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    recommended that data are collected using validated measure(s) of HRQoL, including EQ-5D. Source guidance details Comes from guidance...

    Research recommendation
    Published
    26 October 2020

  11. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    recommended that data are collected using validated measure(s) of HRQoL,including EQ-5D. Source guidance details Comes from guidance...

    Research recommendation
    Published
    9 June 2015

  12. Pharmacological management of peripheral spondyloarthritis:- What is the comparative effectiveness and cost effectiveness of standard DMARDs for managing peripheral spondyloarthritis, and is this effectiveness affected by differences in dose escalation protocols?

    outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...

    Research recommendation
    Published
    4 May 2017

  13. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  14. Biological therapies for peripheral spondyloarthritis:- What is the effectiveness and cost effectiveness of biological DMARDs in people with persistent peripheral spondyloarthritis (excluding psoriatic arthritis) or undifferentiated spondyloarthritis?

    outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...

    Research recommendation
    Published
    4 May 2017

  15. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

    Technology appraisal guidance
    Published
    23 January 2013
    View recommendations

    Sections for TA272